Trevena, Inc. CEO to Present at the 2011 UBS Global Life Sciences Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines, announced today that it will participate in the 2011 UBS Global Life Sciences Conference in New York. Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will make a presentation on Wednesday, September 21, 2011 at 10:00 a.m. EDT. Trevena’s most advanced program, TRV027, is a biased AT1R ligand currently in Phase 2 studies for the treatment of acute heart failure. The company also has discovery-stage and preclinical programs targeting opioid receptors for pain.

Back to news